A 29-year-old female suffered from intense headaches for 15 to 20 days in a month from December 2014. The pain would start above the eyes and become severe towards the left side of the head and last the whole day till she slept. Sometimes it was accompanied by chill and fever and the temperature would go up to 102o F and would only come down if she took medicine. As the CT scan showed no abnormality she attributed her condition to excessive work pressure and consequent mental stress. She took allopathic medicines for about a year but as she developed burning sensation in her stomach she discontinued them in December 2015. She then switched over to homoeopathic treatment and was 75% better by January 2017. The frequency of headaches had reduced to once a week, was less severe, and lasted up to 3-4 hours each time. In June 2017, as there was no further improvement and it was a lot of financial burden, she stopped the treatment. After about 15 days the headaches returned with the same intensity and frequency she had before starting the medicines. So, she had to resume the treatment. It took eight months to reach 75% improvement which seemed to have reached a plateau. So she started looking for alternatives that could give total relief. Soon she came to know about vibrionics. She stopped the homoeopathic treatment and on 15 February 2018, she consulted the practitioner who gave the following:
CC4.10 Indigestion + CC11.3 Headaches + CC11.4 Migraines + CC15.1 Mental & Emotional tonic + CC19.5 Sinusitis…6TD
On 30 April 2018, the patient reported she was feeling much better than before as she had headache only once in 10-15 days during the past 2½ months; the intensity was much less and the headache lasted for 2-3 hours. On 30 June, as the headaches were less frequent and would last only for about an hour, the dosage was reduced to TDS. The headache became progressively milder and disappeared by 30 September 2018, giving her the much needed relief. She preferred to continue the remedy at TDS for a few more months as she dreaded the possibility of a recurrence. In April 2019 the dosage was reduced to OD which is still being continued as of April 2020 since the patient is not willing to stop or taper it down any further.